Strategic Acquisition RPC recently expanded its product portfolio by acquiring the Peracidin product line from Angelini Pharma, signaling a growth trajectory and new sterilant offerings that can open cross-sell opportunities with dialysis centers and life science customers.

Portfolios & Reach With over 500 products worldwide and operations in multiple U.S. locations, RPC demonstrates a broad catalog and regional presence that can be leveraged to upsell complementary devices, consumables, and training services to existing dialysis and medical facility customers.

Expertise & Standards AAMI and NANT membership, plus corporate and committee involvement, highlights a trusted position in high-quality standards and technical education, creating opening for premium training contracts, certification programs, and consulting engagements with clinics and distributors.

Workforce Experience A seasoned team with long-tenure dialysis expertise presents a compelling value proposition for service contracts, on-site support, and educational partnerships targeted at clinics seeking reliable technical support and knowledge transfer.

Growth & Partnerships The combination of a revenue range indicative of a scalable SMB and recent asset acquisition suggests rapid expansion potential; identify OEM, distributor, and hospital procurement partnerships to accelerate market penetration and cross-ecosystem collaborations.